
What is claimed is:

1. A compound of Formula I or a pharmaceutically acceptable salt thereof:



(I)

wherein:

ring A is selected from the group consisting of phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl;

n is 1, 2, or 3;

T is CR_1R_2 or O;

W is CR_4R_5 or O;

U is CR_6R_7;

X is CR_8R_9;

V is CR_3 or N;

Y is NR_{10}, O or absent;

Z is $(CR_{12}R_{13})_m$;

R is halogen or deuterium; and

p is 0, 1, 2, 3, or 4;

and further wherein:

m is 1, 2, 3, or 4;

R_1, R_2, R_4, and R_5 are each, independently, selected from the group consisting of H, halogen, and deuterium;

or, alternatively, R_2 and R_5 together with the carbon atoms to which they are attached, form a single bond;

R_3 is selected from the group consisting of H, deuterium, halogen, hydroxyl, and cyano;

or, alternatively, R_3 and R_1, together with the carbon atoms to which they are attached, form a C_3-C_5 cycloalkyl;

or, alternatively, R_3 and R_4, together with the carbon atoms to which they are attached, form a C_3-C_5 cycloalkyl;

R_6, R_7, R_8, R_9, and R_{11} are each, independently, selected from the group consisting of H, halogen, and deuterium;

R_{10} is selected from the group consisting of H, unsubstituted C_1-C_3alkyl, and C_1-C_3alkyl substituted with one or more halogen atoms; and

each R_{12} and R_{13} is, independently, selected from the group consisting of H, halogen, deuterium, unsubstituted C_1-C_3alkyl, and C_1-C_3alkyl substituted with one or more halogen atoms.

2. The compound of claim 1, wherein n is 1.

3. The compound of claim 1, wherein n is 2.

4. The compound of any one of claims 1-3, wherein ring A is phenyl.

5. The compound of any one of claim 1-3, wherein ring A is pyridinyl.

6. The compound of any one of claims 1-5, wherein Y is O.

7. The compound of any one of claims 1-5, wherein Y is absent.

8. The compound of any one of claims 1-3, wherein ring A is phenyl and Y is O.

9. The compound of any one of claims 1-3, wherein ring A is pyridinyl and Y is O.

10. The compound of any one of claims 1-3, wherein ring A is phenyl and Y is absent.

11. The compound of any one of claims 1-3, wherein ring A is pyridinyl and Y is absent.

12. The compound of any one of the preceding claims, wherein T is CR_1R_2.

13. The compound of any one of the preceding claims, wherein T is O.

14. The compound of any one of the preceding claims, wherein W is CR_4R_5.

15. The compound of any one of the preceding claims, wherein W is O.

16. The compound of any one of the preceding claims, wherein V is CR_3.

17. The compound of any one of claims 1-11, wherein T is CR_1R_2, W is CR_4R_5, and V is CR_3.

18. The compound of any one of the preceding claims, wherein m is 1 or 2.

19. The compound of any one of claim 1-17, wherein m is 3 or 4.

20. The compound of any one of claims 1-3, wherein ring A is phenyl, T is CR_1R_2, W is CR_4R_5, and V is CR_3.

21. The compound of claim 20, wherein Y is absent.

22. The compound of claim 20, wherein Y is O.

23. The compound of any one of claims 20-22, wherein m is 1 or 2.

24. The compound of any one of claims 20-22, wherein m is 3 or 4.

25. The compound of any one of claims 1-3, wherein ring A is pyridinyl, T is CR_1R_2, W is CR_4R_5, and V is CR_3.











26. The compound of claim 25, wherein Y is absent.


27. The compound of claim 25, wherein Y is O.









28. The compound of any one of claims 25-27, wherein m is 1 or 2.











29. The compound of any one of claims 25-27, wherein m is 3 or 4.











30. The compound of claim 1, wherein the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of:












,

,

,

,

,

,

,

,

,

,









,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

, and

.

5

31. A compound of Formula II or a pharmaceutically acceptable salt thereof:



(II)

wherein:

ring A is selected from the group consisting of phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl;

n is 1, 2, or 3;

T is CR_1R_2 or O;

W is CR_4R_5 or O;

U is CR_6R_7;

X is CR_8R_9;

V is CR_3 or N;

Y is NR_{10}, O or absent;

Z is $(CR_{12}R_{13})_m$;

R is halogen or deuterium; and

p is 0, 1, 2, 3, or 4;

and further wherein:

m is 2, 3, 4, or 5 when Y is absent; or

m is 1, 2, 3, or 4 when Y is NR_{10} or O;

R_1, R_2, R_4, and R_5 are each, independently, selected from the group consisting of H, halogen, and deuterium;

or, alternatively, R_2 and R_5 together with the carbon atoms to which they are attached, form a single bond;

R_3 is selected from the group consisting of H, deuterium, halogen, hydroxyl, and cyano;

or, alternatively, R_3 and R_1, together with the carbon atoms to which they are attached, form a C_3-C_5 cycloalkyl;

or, alternatively, R_3 and R_4, together with the carbon atoms to which they are attached, form a C_3-C_5 cycloalkyl;

R_6, R_7, R_8, R_9, and R_{11} are each, independently, selected from the group consisting of H, halogen, and deuterium;

R_{10} is selected from the group consisting of H, unsubstituted C_1-C_3alkyl, and C_1-C_3alkyl substituted with one or more halogen atoms; and

each R_{12} and R_{13} is, independently, selected from the group consisting of H, halogen, deuterium, unsubstituted C_1-C_3alkyl, and C_1-C_3alkyl substituted with one or more halogen atoms.

32. The compound of claim 31, wherein n is 1.

33. The compound of claim 31, wherein n is 2.

34. The compound of any one of claims 31-33, wherein ring A is phenyl.

35. The compound of any one of claims 31-33, wherein ring A is pyridinyl.

36. The compound of any one of claims 31-35, wherein Y is O.

37. The compound of any one of claims 31-35, wherein Y is absent.

38. The compound of any one of claims 31-33, wherein ring A is phenyl and Y is O.

39. The compound of any one of claims 31-33, wherein ring A is pyridinyl and Y is O.

40. The compound of any one of claims 31-33, wherein ring A is phenyl and Y is absent.

41. The compound of any one of claims 31-33, wherein ring A is pyridinyl and Y is absent.

42. The compound of any one of claims 31-41, wherein T is CR_1R_2.

43. The compound of any one of claims 31-41, wherein T is O.

44. The compound of any one of claims 31-43, wherein W is CR_4R_5.

45. The compound of any one of claims 31-43, wherein W is O.

46. The compound of any one of claims 31-45, wherein V is CR_3.

47. The compound of any one of claims 31-41, wherein T is CR_1R_2, W is CR_4R_5, and V is CR_3.

48. The compound of any one of claims 31-47, wherein m is 1 or 2.

49. The compound of any one of claims 31-47, wherein m is 3 or 4.

50. The compound of any one of claims 31-33, wherein ring A is phenyl, T is CR_1R_2, W is CR_4R_5, and V is CR_3.

51. The compound of claim 50, wherein Y is absent.

52. The compound of claim 50, wherein Y is O.

53. The compound of any one of claims 50-52, wherein m is 1 or 2.

54. The compound of any one of claims 50-52, wherein m is 3 or 4.

55. The compound of any one of claims 31-33, wherein ring A is pyridinyl, T is CR_1R_2, W is CR_4R_5, and V is CR_3.











56. The compound of claim 55, wherein Y is absent.









57. The compound of claim 55, wherein Y is O.

58. The compound of any one of claims 55-57, wherein m is 1 or 2.










59. The compound of any one of claims 55-57, wherein m is 3 or 4.

60. The compound of claim 31, wherein the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

- 187 -


,

,

,

,

,

,

,

, and

.

5

61. A pharmaceutical composition comprising a compound of any one of claims 1-60 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

62. A method of treating narcolepsy in a subject in need thereof comprising administering to the subject a compound of any one of claims 1-60 or a pharmaceutically acceptable salt thereof, or a composition according to claim 61.

63. A method of treating cataplexy in a subject in need thereof comprising administering to the subject a compound of any one of claims 1-60 or a pharmaceutically acceptable salt thereof, or a composition according to claim 61.

64. Use of a compound of any one of claims 1-60 or a pharmaceutically acceptable salt thereof, or a composition according to claim 61 for the manufacture of a medicament for narcolepsy.

65. Use of a compound of any one of claims 1-60 or a pharmaceutically acceptable salt thereof, or a composition according to claim 61 for the manufacture of a medicament for cataplexy.

66. A compound of any one of claims 1-60 or a pharmaceutically acceptable salt thereof, or a composition according to claim 61 for use in a method of treating narcolepsy in a subject in need thereof.

67. A compound of any one of claims 1-60 or a pharmaceutically acceptable salt thereof, or a composition according to claim 61 for use in a method of treating cataplexy in a subject in need thereof.